Synthesis and Evaluation of Some Substituted Heterocyclic Fluconazole Analogues as Antifungal Agents

SHUDONG WANG^{1,†}, LEI ZHANG^{2,3,†}, YONGSHENG JIN², JIN HAO TANG¹, HUA SU¹, SHICHONG YU^{2,*} and HAIXIANG REN^{1,*}

¹Department of Pharmacy, General Hospital of Nanjing Military Region, Chinese People's Liberation Army, Zhongshan East Road 305, Nanjing 210002, P.R. China

²College of Pharmacy, Second Military Medical University, Guohe Road 325, Shanghai 200433, P.R. China

³College of Pharmacy, Yantai University, Qingquan Road 30, Yantai 264005, P.R. China

*Corresponding authors: E-mail: yuscc1008@163.com; haixiangreng@163.com

†Shudong Wang and Lei Zhang contributed equally to this work

Received: 25 June 2013;

Accepted: 25 September 2013;

Published online: 15 April 2014;

AJC-15026

A new series of fluconazole analogues of 1-(1H-1,2,4-triazol-1-yl)-2-(2,4-difluoro-phenyl)-3-4-(substituted-heterocyclic ring-1H-1,2,3-triazol-1-yl)-2-propanols (**1-10**) were designed, synthesized and evaluated as antifungal agents. Preliminary antifungal tests showed that most of the title compounds exhibited moderate activity with broad spectrum against eight human pathogenic fungi *in vitro*, compounds **1** and **6** had the best antifungal activity against *Candida albicans* with the value of MIC₈₀ = 0.5 µg/mL respectively.

Keywords: Triazole, Synthesis, Antifungal activity, 1,3,4-Oxadiazol.

INTRODUCTION

During the past few decades, fungal infections are the commonly prevalent diseases from which a large proportion of the human population suffers¹⁻⁵. The increased emergence of both the superficial and systemic fungal infections has led to the massive increase in the rate of mortality, especially in the immuno-compromised individuals, those suffering from tuberculosis, cancer or AIDS^{6,7}. In clinic, azoles, especially triazole antifungal agents, were used most widely and efficiently. For example, fluconazole, voriconazole and itraconazole, presently play an important role in the treatment of fungal infections. However, their clinical use has been limited by the emergence of drug resistance, high risk of toxicity, insufficiencies in their antifungal activity and undesirable side effects⁸⁻¹⁰. Hence, there is still a need to develop the safe and efficient chemotherapeutic agents with potent broad spectrum antifungal activities¹⁰.

EXPERIMENTAL

Analytical TLC was carried out on Silica Gel 60 F254 plates (E. Merck) with detection by fluorescence and/or by charring with 10 % (v/v) H₂SO₄ in EtOH. Column chromatograph was performed on silica gel (200-300 mesh, Qindao Ocean Chemical Co., China). All chemicals and solvents were purchased from commercial sources unless specified otherwise. ¹H and ¹³C NMR spectra were recorded in CDCl₃, using

TMS as internal standard NMR solvent. Mass spectra were performed on an API-3000 LC-MS and Agilent Q-TOF-MS spectrometer.

Synthesis of target compounds: The general synthetic methodology for the preparation of title compounds is outlined in **Scheme-I**. The key intermediate **1** was synthesized by the reported procedure^{11,12}, the triazolone-containing side chains were prepared *via* four steps. Various substituted benzoic acid **1-10a** were converted to methyl benzoate **1-10b** by reacting with methanol, followed by treating with hydrazine hydrate to give benzohydrazide **1-10c**. **1-10d** were synthesized by reacting the **1-10c** with carbon disulphide in presence of KOH and conc sulfuric acid and then reacted with 3-bromo-1-propyne to give the side chains **1-10e**. The compounds **1-10** were carried out under the click-reaction^{13,14} condition in the presence of CuSO₄ and sodium ascorbate. All the title compounds (**1-10**) described above were characterized by ESI and NMR spectroscopic analysis.

Compound 1: Yellow oil, yield: 81 %; ¹H NMR (300 MHz, CDCl₃) δ 8.02 (s, 1H), 7.94-7.73 (m, 3H), 7.50-7.26 (m, 4H), 6.78-6.70 (dd, 2H, *J* = 16.8, 7.3 Hz), 5.35 (s, 1H), 4.89-4.84 (d, 1H, *J* = 14.2 Hz), 4.75-4.72 (m, 2H), 4.63-4.46 (m, 2H), 4.33-4.29 (d, 1H, *J* = 14.3 Hz), 2.69 (s, 3H); [M + H]⁺ 511.14, found 511.57.

Compound 2: Yellow oil, yield: 83 %; ¹H NMR (300 MHz, CDCl₃) δ 8.16-7.67 (m, 5H), 7.41-7.39 (m, 3H), 6.72-

Scheme-I: Synthesis of the target compounds 1-10

6.69 (m, 2H), 5.36 (s, 1H), 4.88-4.84 (d, 1H, $J = 14.3$ Hz), 4.78-4.62 (m, 2H), 4.61-4.42 (m, 2H), 4.33-4.29 (d, 1H, $J = 14.1$ Hz), 2.43 (s, 3H); $[M + H]^+$ 511.14, found 511.64.

Compound 3: Yellow oil, yield: 86 %; ^1H NMR (300 MHz, CDCl_3) δ 8-7.80 (m, 5H), 7.68-7.60 (m, 1H), 7.52-7.27 (m, 1H), 6.87-6.66 (m, 4H), 4.87-4.86 (m, 1H), 4.79-4.69 (m, 3H), 4.60-4.47 (m, 1H), 3.71-3.67 (d, 1H, $J = 12.8$ Hz), 3.56-3.51 (d, 1H, $J = 12.8$ Hz), 2.38 (3H, s); $[M + H]^+$ 511.14, found 511.51.

Compound 4: Pale yellow oil, yield: 88 %; ^1H NMR (300 MHz, CDCl_3) δ 8 (s, 1H), 7.84 (s, 1H), 7.75 (s, 1H), 7.45-7.31 (m, 3H), 6.85-6.62 (m, 3H), 4.88-4.83 (d, 1H, $J = 14.2$ Hz), 4.74-4.72 (d, 2H, $J = 6.5$ Hz), 4.56-4.55 (d, 2H, $J = 2.9$ Hz), 4.32-4.27 (d, 1H, $J = 14.3$ Hz); $[M + H]^+$ 586.09, found 586.42.

Compound 5: Yellow oil, yield: 82 %; ^1H NMR (300 MHz, CDCl_3) δ 8.02 (s, 1H), 7.86 (s, 1H), 7.76 (s, 1H), 7.47-7.31 (m, 1H), 6.85-6.68 (m, 2H), 4.89-4.84 (d, 1H, $J = 14.1$ Hz), 4.79-4.67 (d, 2H, $J = 14.2$ Hz), 4.61-4.56 (d, 2H, $J = 7.4$ Hz), 4.32-4.27 (d, 1H, $J = 14.2$ Hz); $[M + H]^+$ 568.08, found 568.35.

Compound 6: Brown oil, yield: 81 %; ^1H NMR (300 MHz, CDCl_3) δ 8.06-7.71 (4H, m), 7.52-7.29 (3H, m), 6.80-6.74 (3H, m), 5.18-5.16 (1H, d, $J = 6.2$ Hz), 4.95-4.68 (4H, m), 4.56-4.54 (1H, d, $J = 6$ Hz), 2.63-2.61 (2H, d, $J = 6.1$ Hz), 1.68 (2H, m), 1.45-1.12 (3H, m); $[M + H]^+$ 538.17, found 538.55.

Compound 7: Yellow oil, yield: 85 %; ^1H NMR (300 MHz, CDCl_3) δ 8.11-7.74 (m, 4H), 7.52-7.29 (m, 3H), 6.82-6.74 (m, 3H), 5.17-5.15 (d, 1H, $J = 6.2$ Hz), 4.85-4.69 (m, 4H), 4.57-4.53 (d, 1H, $J = 12$ Hz), 2.62-2.58 (m, 2H), 1.68-1.64 (m, 4H), 1.45-1.22 (m, 3H); $[M + H]^+$ 552.18, found 552.57.

Compound 8: Yellow oil, yield: 83 %; ^1H NMR (300 MHz, CDCl_3) δ 8.01 (s, 1H), 7.82 (s, 1H), 7.74 (1H, s), 7.39-7.31 (dd, 3H, $J = 15.5, 9.1$ Hz), 6.85-6.68 (m, 3H), 4.86-4.81 (d, 1H, $J = 14.3$ Hz), 4.74-4.73 (d, 2H, $J = 2.8$ Hz), 4.54-4.53 (d, 2H, $J = 2.1$ Hz), 4.34-4.29 (d, 1H, $J = 14.3$ Hz), 1.25 (s, 9H); $[M + H]^+$ 552.18, found 552.57.

Compound 9: Yellow oil, yield: 89 %; ^1H NMR (300 MHz, CDCl_3) δ 8.14-8.11 (d, 2H, $J = 8.1$ Hz), 8.04 (s, 1H), 7.85 (s, 1H), 7.84-7.73 (m, 3H), 7.37 (m, 1H), 6.82-6.65 (m, 2H), 4.89-4.84 (d, 1H, $J = 14.4$ Hz), 4.80-4.69 (q, 2H, $J = 14.3$ Hz), 4.56 (s, 2H), 4.35-4.31 (d, 1H, $J = 14.2$ Hz), 2.63-2.60 (m, 2H), 1.66-1.65 (m, 6H), 1.45-1.15 (m, 3H); $[M + H]^+$ 566.20, found 566.62.

Compound 10: Yellow oil, yield: 80 %; ^1H NMR (300 MHz, CDCl_3) δ 8.0-7.96 (d, 3H, $J = 13.4$ Hz), 7.83-7.76 (m, 2H), 7.61-7.42 (m, 3H), 7.39-7.31 (m, 1H), 6.86-6.55 (m, 2H), 5.46 (s, 1H), 4.87-4.82 (d, 1H, $J = 14.3$ Hz), 4.77-4.63 (m, 2H), 4.53 (s, 1H), 4.35-4.40 (d, 1H, $J = 14.3$ Hz); $[M + H]^+$ 496.12, found 496.43.

RESULTS AND DISCUSSION

All the title compounds (**1-10**) were screened for anti-fungal activity against eight pathogenic fungi. The *in vitro* minimal inhibitory concentrations (MICs) of the compounds were determined by the micro-broth dilution method in 96-well microtest plates according to the methods defined by the National Committee for Clinical Laboratory Standards (NCCLS)¹⁵. Itraconazole (ICZ) and fluconazole (FCZ) served as the positive controls were obtained from their respective manufacturers. Table-1 showed that all the synthesized compounds show moderate activity against all the tested fungal pathogens. Most of our compounds showed the good antifungal

TABLE-1
ANTIFUNGAL ACTIVITY OF THE TARGET COMPOUNDS *in vitro* (MIC₈₀: µg/mL)

Compd.	R	C. alb Y0109	C. alb SC5314	C. pra	C. neo	C. gla	A. fum	T. rub	M. gyp
1	2-CH ₃	0.5	0.5	0.5	0.5	0.5	> 64	64	> 64
2	3-CH ₃	1	2	1	0.5	1	> 64	32	32
3	4-CH ₃	1	4	2	1	0.25	64	8	16
4	3,5-NO ₂	1	1	1	2	2	> 64	64	64
5	2,3,4,5,6-F	2	2	2	2	2	> 64	64	64
6	4-(CH ₂) ₂ CH ₃	0.5	0.5	8	8	0.5	> 64	32	64
7	4-(CH ₂) ₃ CH ₃	2	2	16	8	2	> 64	> 64	> 64
8	4-C(CH ₂) ₃	4	2	4	2	0.5	> 64	32	32
9	4-(CH ₂) ₄ CH ₃	8	8	16	4	1	32	16	16
10	H	1	4	4	0.5	1	> 64	> 64	> 64
ICZ	-	8	4	8	4	8	8	2	2
FCZ	-	0.5	0.5	1	1	1	> 64	8	8

Abbreviations: C. alb. Y0109 = *Candida albicans* Y0109; C. alb. SC5314 = *Candida albicans* SC5314; C. pra. = *Candida parapsilosis*; C. neo. = *Cryptococcus neoformans*; C. gla. = *Candida glabrata*; A. fum. = *Aspergillus fumigatus*; T. rub. = *Trichophyton rubrum*; M. gyp. = *Microsporum gypseum*. ICZ = Itraconazole; FCZ = Fluconazole.

activities than the positive control itraconazole. It is noted that the MIC₈₀ values of compounds **1** and **6** were equal or a little bit lower than that of fluconazole and itraconazole against *C. albicans*, *C. parapsilosis*, *C. neoformans* and *C. glabrata*.

Conclusion

In summary, a novel series of antifungal agents have been successfully designed and synthesized. Antifungal activity assay *in vitro* indicates that most of the compounds showed moderate antifungal activities against systemic pathogenic fungi. Some compounds (such as compd. **1** and **6**) show highly antifungal activity with broad spectrum, which were valuable for further studies.

ACKNOWLEDGEMENTS

This work was supported by the National Natural Science Foundation of China (Nos. 20772153), the Creativity and Innovation Training Program of Second Military Medical University (Grant No. ZD2013029).

REFERENCES

- P.G. Pappas, B.D. Alexander, D.R. Andes, S. Hadley, C.A. Kauffman, A. Freifeld, E.J. Anaissie, L.M. Brumble, L. Herwaldt, J. Ito, D.P. Kontoyiannis, G.M. Lyon, K.A. Marr, V.A. Morrison, B.J. Park, T.F. Patterson, T.M. Perl, R.A. Oster, M.G. Schuster, R. Walker, T.J. Walsh, K.A. Wannemuehler and T.M. Chiller, *Clin. Infect. Dis.*, **50**, 1101 (2010).
- M.D. Richardson, *J. Antimicrob. Chemother.*, **56**(suppl 1), 5 (2005).
- D.W. Warnock, *Nippon Ishinkin Gakkai Zasshi*, **48**, 1 (2007).
- C. Garcia-Vidal, D. Viasus and J. Carratalà, *Curr. Opin. Infect. Dis.*, **26**, 270 (2013).
- M.H. Miceli, J.A. Díaz and S.A. Lee, *Lancet Infect. Dis.*, **11**, 142 (2011).
- J.R. Wingard and H. Leather, *Biol. Blood Marrow Transplant*, **10**, 73 (2004).
- S.K. Fridkin and W.R. Jarvis, *Clin. Microbiol. Rev.*, **9**, 499 (1996).
- M.A. Pfaller, *Am. J. Med.*, **125**, S3 (2012).
- D.S. Johnson and J.J. Li, *The Art of Drug Synthesis*, **7**, 71 (2007).
- M. Canuto and F. Roderio, *Lancet Infect. Dis.*, **2**, 550 (2002).
- T. Konosu, Y. Tajima, N. Takeda, T. Miyaoka, M. Kasahara, H. Yasuda and S. Oida, *Chem. Pharm. Bull. (Tokyo)*, **38**, 2476 (1990).
- S.C. Yu, X.Y. Chai, H. Hu, Y. Yan, Z. Guan, Y. Zou, Q. Sun and Q. Wu, *Eur. J. Med. Chem.*, **45**, 4435 (2010).
- B.G. Wang, S.C. Yu, X.Y. Chai, Y.Z. Yan, H.G. Hu and Q.Y. Wu, *Chin. Chem. Lett.*, **22**, 519 (2011).
- Y. Zou, Q. Zhao, J. Liao, H. Hu, S. Yu, X. Chai, M. Xu and Q. Wu, *Bioorg. Med. Chem. Lett.*, **22**, 2959 (2012).
- National Committee for Clinical Laboratory Standards, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts Approved standard. Document M27-A2, National Committee for Clinical Laboratory Standards, Wayne, PA (2002).